Center for Vaccine Development and Global Health at the University of Maryland School of Medicine, Baltimore, MD.
Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.
Clin Infect Dis. 2019 Mar 7;68(Suppl 2):S171-S176. doi: 10.1093/cid/ciy1118.
The health consequences of typhoid, including increasing prevalence of drug-resistant strains, can stress healthcare systems. While vaccination is one of the most successful and cost-effective health interventions, vaccine introduction can take years and require considerable effort. The Typhoid Vaccine Acceleration Consortium (TyVAC) employs an integrated, proactive approach to accelerate the introduction of a new typhoid conjugate vaccine to reduce the burden of typhoid in countries eligible for support from Gavi, the Vaccine Alliance. TyVAC and its partners are executing a plan, informed by prior successful vaccine introductions, and tailored to the nuances of typhoid disease and the typhoid conjugate vaccine. The iterative process detailed herein summarizes the strategy and experience gained from the first 2 years of the project.
伤寒病的健康后果，包括耐药菌株的日益流行，可能会给医疗保健系统带来压力。虽然疫苗接种是最成功和最具成本效益的卫生干预措施之一，但疫苗的推出可能需要数年时间，并需要大量的努力。伤寒疫苗加速联盟（TyVAC）采用综合、主动的方法来加速引入一种新的伤寒结合疫苗，以减轻有资格获得疫苗联盟支持的国家的伤寒负担。TyVAC 及其合作伙伴正在执行一项计划，该计划以先前成功的疫苗引入为依据，并根据伤寒病和伤寒结合疫苗的细微差别进行调整。本文详细介绍的迭代过程总结了该项目头两年的策略和经验。
